Filing Details

Accession Number:
0000950142-21-000146
Form Type:
13G Filing
Publication Date:
2021-01-14 19:00:00
Filed By:
Temasek Holdings (private) Ltd
Company:
Gracell Biotechnologies Inc.
Filing Date:
2021-01-15
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Temasek Holdings (Private) Limited 0 49,509,702 0 49,509,702 49,509,702 15.1%
Fullerton Management Pte Ltd 0 49,509,702 0 49,509,702 49,509,702 15.1%
Temasek Life Sciences Private Limited 0 49,509,702 0 49,509,702 49,509,702 15.1%
TLS Beta Pte. Ltd 0 49,509,702 0 49,509,702 49,509,702 15.1%
Filing

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 13G 

Under the Securities Exchange Act of 1934

 

(Amendment No. )* 

 
Gracell Biotechnologies Inc.
(Name of Issuer)
 
Ordinary Shares, par value US$0.0001 per share
(Title of Class of Securities)
 
38406L103
(CUSIP Number)
 
January 7, 2021
(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  Rule 13d-1(b)
  Rule 13d-1(c)
  Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
   

 

CUSIP No. 38406L103 SCHEDULE 13G Page 2 of 9

 

 

1

NAME OF REPORTING PERSON

 

Temasek Holdings (Private) Limited

 
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a) 

(b) 

3

SEC USE ONLY

 

 

 
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Singapore

 

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

49,509,702

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

49,509,702

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

49,509,702

 
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

15.1%*

 
12

TYPE OF REPORTING PERSON

 

HC

 

 

* This percentage calculation is based on 327,815,996 Ordinary Shares outstanding, according to the Issuer’s prospectus dated January 7, 2021.

 

   

 

CUSIP No. 38406L103 SCHEDULE 13G Page 3 of 9

 

 

1

NAME OF REPORTING PERSON

 

Fullerton Management Pte Ltd

 
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a) 

(b) 

3

SEC USE ONLY

 

 

 
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Singapore

 

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

49,509,702

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

49,509,702

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

49,509,702

 
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

15.1%*

 
12

TYPE OF REPORTING PERSON

 

HC

 

 

* This percentage calculation is based on 327,815,996 Ordinary Shares outstanding, according to the Issuer's prospectus dated January 7, 2021

 

   

 

CUSIP No. 38406L103 SCHEDULE 13G Page 4 of 9

 

 

1

NAME OF REPORTING PERSON

 

Temasek Life Sciences Private Limited

 
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a) 

(b) 

3

SEC USE ONLY

 

 

 
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Singapore

 

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

49,509,702

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

49,509,702

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

49,509,702

 
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

15.1%*

 
12

TYPE OF REPORTING PERSON

 

HC

 

 

* This percentage calculation is based on 327,815,996 Ordinary Shares outstanding, according to the Issuer's prospectus dated January 7, 2021.

 

   

 

CUSIP No. 38406L103 SCHEDULE 13G Page 5 of 9

 

 

1

NAME OF REPORTING PERSON

 

TLS Beta Pte. Ltd.

 
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

 

(a) 

(b) 

3

SEC USE ONLY

 

 

 
4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Singapore

 

NUMBER OF

SHARES

BENEFICIALLY OWNED

BY EACH REPORTING

PERSON

WITH

5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

49,509,702

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

49,509,702

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

49,509,702

 
10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

15.1%*

 
12

TYPE OF REPORTING PERSON

 

CO

 

 

* This percentage calculation is based on 327,815,996 Ordinary Shares outstanding, according to the Issuer's prospectus dated January 7, 2021.

 

   

 

CUSIP No. 38406L103 SCHEDULE 13G Page 6 of 9

 

ITEM 1
     
(a) Name of Issuer
   
  Gracell Biotechnologies Inc. (the “Issuer”)
     
(b) Address of Issuer’s Principal Executive Offices
     
  Building 12, Block B, Phase II
  Biobay Industrial Park, 218 Sangtian St., Suzhou Industrial Park
  People's Republic of China
     
ITEM 2
   
(a) Names of Persons Filing
     
  (i) Temasek Holdings (Private) Limited (“Temasek”)
   
 

(ii) Fullerton Management Pte Ltd (“FMPL”)

   
 

(iii) Temasek Life Sciences Private Limited (“TLS”)

   
 

(iv) TLS Beta Pte. Ltd. (“TLS Beta” and, together with Temasek, FMPL and TLS, the “Reporting Persons”)

     
(b) Address of Principal Business Office or, if none, Residence
     
 

Each of the Reporting Persons:

   
 

60B Orchard Road

 

#06-18 Tower 2

 

The Atrium@Orchard

 

Singapore 238891

     
(c) Citizenship
   
 

Each of the Reporting Persons: Singapore

     
(d) Title of Class of Securities
     
 

Ordinary Shares, par value US$0.0001 per share

     
(e) CUSIP Number
     
 

38406L103. This CUSIP number applies to the American depositary shares, each representing five Ordinary Shares of the Issuer.

   
ITEM 3

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

   

Not applicable.

   
ITEM 4

Ownership

   

Ownership information with respect to Temasek, FMPL, TLS and TLS Beta is incorporated by reference through items (5) through (9) and (11) of the cover page for each entity.

 

TLS Beta shares the power to vote and the power to dispose of 49,509,702 Ordinary Shares held directly by it with Temasek, FMPL and TLS. TLS Beta is wholly owned by TLS, which is wholly owned by FMPL, which is wholly owned by Temasek.

   

 

CUSIP No. 38406L103 SCHEDULE 13G Page 7 of 9

 

ITEM 5 Ownership of Five Percent or Less of a Class
   
Not applicable.
   
ITEM 6 Ownership of More than Five Percent on Behalf of Another Person
   
Not applicable.
   
ITEM 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
   
Not applicable.
   
ITEM 8 Identification and Classification of Members of the Group
   
Not applicable.
   
ITEM 9 Notice of Dissolution of Group
   
Not applicable.
   
ITEM 10 Certifications
   
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

   

 

CUSIP No. 38406L103 SCHEDULE 13G Page 8 of 9

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

  January 15, 2021  
     
     
 

TEMASEK HOLDINGS (PRIVATE) LIMITED

 
         
  By:

/s/ Andrew Ang Lye Whatt

 
  Name: Andrew Ang Lye Whatt  
  Title: Authorised Signatory  

  

 

FULLERTON MANAGEMENT PTE LTD

 
         
  By:

/s/ Gregory Tan

 
  Name:

Gregory Tan

 
  Title:

Director

 

 

TEMASEK LIFE SCIENCES PRIVATE LIMITED

 
         
  By:

/s/ Lim Siew Lee Sherlyn

 
  Name:

Lim Siew Lee Sherlyn

 
  Title:

Director

 

 

TLS BETA PTE. LTD.

 
         
  By:

/s/ Zahedah Abdul Rashid

 
  Name:

Zahedah Abdul Rashid

 
  Title:

Director

 

 

 

 

   

 

CUSIP No. 38406L103 SCHEDULE 13G Page 9 of 9

 

 

LIST OF EXHIBITS

Exhibit No. Description
A     Joint Filing Agreement

 

   

 

Exhibit A

 

Joint Filing Agreement

 

In accordance with Rule 13d-1(k) promulgated under the U.S. Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other reporting persons on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Ordinary Shares, par value $0.0001 per share, of Gracell Biotechnologies Inc., a Cayman Islands exempted company, and that this Agreement may be included as an Exhibit to such joint filing. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

 

IN WITNESS WHEREOF, the undersigned hereby execute this Agreement as of January 15, 2021.

 

 

TEMASEK HOLDINGS (PRIVATE) LIMITED

 
         
  By:

/s/ Andrew Ang Lye Whatt

 
  Name: Andrew Ang Lye Whatt  
  Title: Authorised Signatory  

  

 

FULLERTON MANAGEMENT PTE LTD

 
         
  By:

/s/ Gregory Tan

 
  Name:

Gregory Tan

 
  Title:

Director

 

 

TEMASEK LIFE SCIENCES PRIVATE LIMITED

 
         
  By:

/s/ Lim Siew Lee Sherlyn

 
  Name:

Lim Siew Lee Sherlyn

 
  Title:

Director

 

 

TLS BETA PTE. LTD.

 
         
  By:

/s/ Zahedah Abdul Rashid

 
  Name:

Zahedah Abdul Rashid

 
  Title:

Director